Exciting opportunities await at Multiplexdx! Join our innovative team and make a difference in revolutionizing breast cancer diagnostics and treatment. Explore our open positions today and embark on a rewarding journey towards shaping the future of personalized medicine. https://lnkd.in/eRDjCS8k
MultiplexDX International
Biotechnology Research
Rockville, Maryland 2,415 followers
Eliminating cancer misdiagnosis by launching a new diagnostic test in 2023 and operating a boutique oligo house.
About us
MultiplexDX is an international corporation established in 2015 consisting of two units: MultiplexDX Inc. located in Maryland US and MultiplexDX s.r.o. located in Slovakia. Our main goal is to eliminate cancer misdiagnosis by launching 98% accurate, quantitative and accessible diagnostic tests. We also operate a boutique oligohouse offering highly specialized custom oligonucleotides to the research community. Our mission: By transforming breast cancer treatment non-responders into responders and ensuring durable responses, we aim to drastically increase survival rates by at least 50%. Objectives of the company are: i) development of the technologies and the products for molecular diagnostic markets superior to currently available products; ii) core facility service using proprietary Multiplex TM technology iii) development of hi-tech 3D digital pathology services. Find out more about MultiplexDX on our official website and in social media: http://www.multiplexdx.com/ https://www.facebook.com/multiplexdx/ https://twitter.com/@multiplexdx http://bit.ly/MDXGooglePlus https://www.youtube.com/c/multiplexdx
- Website
-
http://multiplexDX.com
External link for MultiplexDX International
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Rockville, Maryland
- Type
- Privately Held
- Founded
- 2015
- Specialties
- pre-adenylated sequencing adapters, miRNA sequencing adapters, cancer diagnostics, FISH core services, and Multilabeled FISH probes
Locations
-
Primary
Get directions
One Research Court Suite 450
MultiplexDX Inc.
Rockville, Maryland 20850, US
-
Get directions
Ilkovicova 8
Bratislava, Bratislavsky kraj 841 04, SK
Employees at MultiplexDX International
Updates
-
Pink October & MultiplexDX: Innovations in breast cancer diagnostics This month focuses on breast cancer awareness and prevention. At MultiplexDX, we are proud to showcase our innovative Multiplex8+ diagnostic test, which holds the potential to transform the way this disease is diagnosed and treated. Our technology enables deeper insights into tumor biology yielding a more accurate diagnosis, which means oncologists can more effectively set up personalized treatment. More information can be found at www.multiplex8.com Join us in this important mission and don't forget to get regular checkups! You can find exact instructions at https://lnkd.in/eM4BnfVq OZ Amazonky - Europa Donna Slovakia #PinkOctober #MultiplexDX #Prevention #Innovation #Diagnosis #BreastCancer
-
-
Excited to support StratifAI in revolutionizing cancer diagnostics! This aligns perfectly with our mission at MultiplexDX to empower oncologists with evidence-based tools for quicker, more accurate treatment decisions. Together, we’re paving the way for personalized medicine and better healthcare outcomes worldwide. https://lnkd.in/gZj5uabH
StratifAI raises €1.5M in pre-seed funding to advance AI-based precision oncology
https://stratifai.com
-
Come and see our poster session at 2024 ASCO Annual Meeting Pavol Cekan Evan Paul
Odlietame do Chicaga na jednu z najprestížnejších a najväčších svetových onkologických konferencií - ASCO Meeting 2024. Vybrali si náš abstrakt a preto budeme mať znova možnosť prezentovať diagnostický test pre pacientky s rakovinou prsníka, Multiplex8+. Ideme reprezentovať firmu MultiplexDX International, Slovensko, ale aj šikovných Slovákov a Slovenky, ktorí sa nestratia ani v medzinárodnej konferencii. Prosím pekne, držte nám prsty a obrovská vďaka za Vašu podporu ... 🙏💙👍
-
-
COME AND SEE OUR POSTER SESSION at ESMO BREAST CANCER 2024: Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping and Prognostic Classification Final Publication Number: 36P Pavol Cekan Evan Paul Barbora Huraiová #ESMOBreast24
-
-
Breaking News: Embarking on a Global Adventure! 🌍✈️ There are 2 main oncology societies in the world that bring together the best oncologists and cancer scientists: the European Society For Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). Every year they organize the most prestigious conferences where the latest knowledge, innovations and breakthroughs in cancer research are presented to create the latest guidelines/recommendations for the treatment of cancer patients. If you are developing an innovative diagnostics or drug against cancer, you want to present the results of your work at ESMO and ASCO conferences, congresses or annual meetings. And we, MultiplexDX International, did it! We have been selected for the ESMO breast cancer conference, which will take place in Berlin this May and also for the prestigious ASCO annual meeting in Chicago, USA this June. Our abstracts have passed the strict scientific selection will get a chance to presented. We will have the opportunity to present our research and innovative diagnostic test, Multiplex8+, to ten thousand oncologists and scientists from all over the world. Moreover, both of our abstracts will be published in a collection of abstracts that will be available to all members of ESMO and ASCO, and thus an even wider professional public will learn about our Multiplex8+. We've made significant strides in spreading awareness about our groundbreaking test and making it accessible to breast cancer patients worldwide. This marks just the beginning of a series of promising developments unfolding this year. Keep your fingers crossed for more good news ahead! 🤞 Congrats Pavol Cekan & Evan Paul We also thank our investors: Neulogy Ventures and Crowdberry.
-
-
Exciting opportunities await at Multiplexdx! Join our innovative team and make a difference in revolutionizing breast cancer diagnostics and treatment. Explore our open positions today and embark on a rewarding journey towards shaping the future of personalized medicine. More info: https://lnkd.in/eRDjCS8k
-
-
Pavol Cekan, CEO of MultiplexDX, and Michaela Šišková, CEO of DNA ERA, discussed women's health at the Forbes Women Summit in Bratislava. Our diagnostic solution, Multiplex8+, in personalized medicine for breast cancer, is already improving patients journey by tailoring treatments to individual patients. #ForbesWomenSummit #BreastCancerAwareness #PersonalisedMedicine #WomenInLeadership #HealthTech #EmpoweringWomen www.multiplex8.com
-
-
🎗️💪 Our recent Forbes interview highlights the impact we aim to make with our innovative breast cancer test, Multiplex8+, backed by solid clinical data. Thanks to all supporters – let's continue pushing boundaries for accessible and life-changing cancer diagnostics, made in Slovakia to the world https://lnkd.in/gQHxJ_ge
Nestáva sa každý deň, aby som bol na obálke časopisu Forbes. Je to pre mňa splnený sen, veľká pocta, za čo som úprimne vďačný. A kedže ide o marcové číslo, tak je to aj pre mňa predčasný darček k narodeninám.
-